Trying to Conceive on a GLP-1: Washout Timing and the Fertility Evidence

The short version

If you are on a GLP-1 and hoping to get pregnant, the plan has two moving parts, and getting them in the right order matters. First, these drugs are not used in pregnancy, so conception is meant to follow a planned washout — the semaglutide labels advise stopping at least two months before a planned pregnancy because the medication clears slowly^1,2. The tirzepatide label is quieter than most coverage implies: it tells you to discontinue once a pregnancy is recognized and to protect against one in the meantime, but it prints no pre-pregnancy window at all³, which is why that timing is a prescriber judgment rather than a number you can look up. Second, the reason a washout matters at all is that these drugs can quietly restore fertility: as weight and insulin resistance fall, ovulation can return — sometimes in women who assumed they could not conceive⁴. But here is the honest twist most coverage misses: a GLP-1 is not a fertility drug, and at least one large real-world study found semaglutide pretreatment was associated with slower, not faster, conception⁷. So the smart move is deliberate timing, not wishful thinking.

This is educational only, not medical advice.

The washout: why you stop before you try

GLP-1 medications linger, and the label is precise about how long. Semaglutide's elimination half-life is about a week, and the Wegovy label states the drug remains present in the circulation for roughly five to seven weeks after the last injection — which is exactly where the "at least two months" instruction comes from¹. The Ozempic label carries the identical two-month wording². Tirzepatide clears somewhat faster, with a half-life of about five to six days, but as noted its label sets no pre-pregnancy window, so a prescriber has to set one³; a 2026 review of GLP-1s and fertility puts the working figure for both molecules at an eight- to ten-week washout before conception⁶. The point of any of it is the same: no active drug on board during the earliest, most vulnerable weeks of development — a window that often passes before a woman knows she is pregnant. This is a plan to make with your clinician before you start trying, not a calculation to run after a positive test.

Why fertility can come back — especially with PCOS

The clearest lever a GLP-1 pulls is weight, and weight is tied to ovulation. It is worth being exact about what international guidance actually says here, because it is often overstated: the 2023 International PCOS Guideline says anti-obesity medications including semaglutide and liraglutide could be considered, alongside active lifestyle intervention, for managing higher weight in adults with PCOS — a conditional recommendation, not a fertility indication — and pairs it with a practice point that clinicians must ensure effective contraception in anyone who could become pregnant, because pregnancy safety data are lacking⁵. As insulin resistance eases, circulating androgens tend to fall and the hormonal signaling that times ovulation can normalize — which is the proposed route by which cycles become more regular and fertility returns⁶. In PCOS trials, GLP-1s have been associated with more regular cycles, more ovulation, and higher pregnancy rates, particularly when combined with metformin⁶. Maternal-fetal medicine reviewers note the same real-world consequence: women previously diagnosed with irregular cycles and unable to conceive have experienced unplanned pregnancies while taking these medications⁴. If you have PCOS, our Ozempic for PCOS guide goes deeper on the weight-and-ovulation mechanism.

The honest counterpoint: a GLP-1 won't speed conception

It is tempting to read "restores ovulation" as "boosts fertility," but the direct evidence pushes back. In a real-world multicenter cohort of nearly 2,000 women with overweight or obesity and infertility, semaglutide pretreatment before fertility care was associated with lower and delayed pregnancy and live-birth rates compared with matched controls — not higher ones⁷. Miscarriage rates did not differ. The authors themselves call for confirmation and caution in preconception counseling⁷. The reasonable takeaway is not that a GLP-1 harms fertility, but that it is a weight-and-metabolic tool, not a conception accelerant — and that the value for a woman trying to conceive is the durable weight loss achieved and then maintained through the washout, not the drug itself at the moment of conception.

Contraception while you are still on it

Until you and your clinician start the planned washout, reliable contraception is part of the plan — because restored ovulation can outpace your expectations. There is also a molecule-specific wrinkle: tirzepatide (Zepbound/Mounjaro) can reduce the effectiveness of oral contraceptives because it slows gastric emptying, so its label advises a backup or non-oral method for four weeks after starting and after each dose increase³. Injectable semaglutide does not carry that warning. Our guide to GLP-1s and birth control breaks that difference down. The logic is the same either way: you want conception to happen on your timeline, after the washout — not as a surprise mid-treatment.

Building the timeline with a provider

A conception plan on a GLP-1 is a sequence: reach and stabilize your weight, confirm contraception is covering you until then, agree on a washout window (at least two months for semaglutide¹, a prescriber-set window for tirzepatide³), start prenatal folate, and only then begin trying. A program that raises pregnancy intentions before the first dose — and maps this sequence with you — is practicing real medicine; our reviews of Form Health and Ro both cover programs with a real clinician in the loop for exactly that conversation. HealthRX is a compounded option that does something similar in a leaner intake: its own published exclusion criteria name "currently pregnant, planning pregnancy, or breastfeeding" directly, rather than leaving conception plans to come up only if you happen to mention them. If a pregnancy happens before the washout, our guide to GLP-1s and pregnancy covers exactly what to do.

Before you build a multi-month sequence like that with a provider, confirm it can actually serve you the whole way through — a coverage claim that doesn't hold up can undo months of planning partway. Healthicare states it's licensed in 44 states while separately naming ten it explicitly cannot serve; fifty minus ten is forty, not forty-four, an arithmetic mismatch on its own page, not a hostile reading of it. Bioverse goes a step further and publishes two different state lists in two different FAQ answers on the same homepage — ten states in one, eighteen in the other. Confirm your own state directly with either before counting on continuity across a washout, a pregnancy, and whatever comes after.

Grading what you have just read

The four claims on this page sit at very different levels, and collapsing them is how people end up misled.

The washout instruction is regulatory fact, not interpretation. Two months before a planned pregnancy for semaglutide is printed in the prescribing information, and the pharmacokinetics behind it — a one-week half-life, five to seven weeks in the circulation — are printed in the same document^1,2. Treat it as fixed.

The contraception advice is strong consensus. The maternal-fetal medicine review recommends that all patients on a GLP-1 use contraception to prevent unintended pregnancy, and the PCOS guideline carries the same instruction as a practice point^4,5. Two independent bodies, same conclusion.

"Fertility can return" is well-supported in direction, weak in magnitude. The mechanism is coherent and clinicians report it happening, but the ovulation and pregnancy-rate trials behind it are small, mostly in PCOS, and largely on liraglutide and exenatide rather than the drug you are probably taking⁶. Expect the effect; do not expect a number.

"A GLP-1 will not speed conception" rests on a single study. It is a large one — nearly 2,000 propensity-matched women — but it is retrospective, drawn from one research network, and its own authors call for prospective confirmation before it changes counseling⁷. One well-run cohort is enough to stop you assuming the opposite. It is not enough to treat as settled.

What would change the picture is a prospective preconception trial randomizing women to a GLP-1 versus lifestyle before fertility care, with live birth as the endpoint. Nobody has run one. Until then, plan the timing carefully and let your clinician set the dates.